GO:0015738 glucuronate transmembrane transport: Transport Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015738 (glucuronate transmembrane transport) describes the movement of glucuronate, a sugar-acid conjugate, across a lipid bilayer from one side of a membrane to the other.
• Glucuronate conjugates are exported from cells mainly by ATP-binding cassette (ABC) transporters of the multidrug resistance-associated protein (MRP/ABCC) family, which act as export pumps for glutathione, glucuronate and sulfate conjugates [5,6].
• Transport of glucuronate conjugates is central to drug disposition, because many drugs and natural compounds are glucuronidated and then must be transported out of cells [1,2].
• The process is not limited to the liver: glucuronate-conjugated metabolites cross the blood-brain barrier and are handled by organic solute transporters in red blood cells [3,8].
• Bacterial ABC transporters that import acidic polysaccharides such as alginate provide structural insight into how glucuronate-containing substrates are recognized and translocated.
• Studying GO:0015738 requires combining transport assays, transporter knockout/knock-in models and metabolomics to link glucuronate flux to physiology and disease [1,5,6].
Description
Glucuronate transmembrane transport (GO:0015738) is the biological process in which glucuronate is transported across a lipid bilayer, from one side of a membrane to the other. Glucuronate is the sugar-acid moiety that is attached to drugs, xenobiotics and endogenous compounds during glucuronidation, a major phase II conjugation reaction catalyzed by uridine diphosphate glucuronosyltransferases (UGTs). Because glucuronidation generally increases water solubility and reduces biological activity, the subsequent export of glucuronate conjugates across membranes is a decisive step that determines how long a compound remains in a cell or in the body [2,5]. The transport step is carried out by dedicated membrane proteins, most prominently ATP-binding cassette (ABC) transporters of the multidrug resistance-associated protein (MRP/ABCC) family, which function as export pumps for conjugates with glutathione, glucuronate or sulfate. These transporters recognize glucuronate-conjugated substrates and use ATP hydrolysis to move them across the plasma membrane or into intracellular compartments [5,6]. In addition to MRP-type exporters, other organic solute transporters can handle glucuronate-containing molecules in specific tissues, such as red blood cells and the blood-brain barrier [3,8]. For researchers, GO:0015738 matters because it connects drug metabolism to membrane transport biology. Defects or inhibition of glucuronate transport can alter drug exposure, contribute to cholestasis and drug-induced toxicity, and change the distribution of dietary and endogenous glucuronate conjugates [1,5,6]. The term is therefore a useful annotation hub for studies of pharmacokinetics, transporter pharmacology and metabolic disease [1,2,6].
glucuronate transmembrane transport At A Glance
| GO ID | GO:0015738 |
|---|---|
| GO term | glucuronate transmembrane transport |
| Ontology | biological_process |
| Synonym | glucuronate transport |
| Definition | The process in which glucuronate is transported across a lipid bilayer, from one side of a membrane to the other. |
| Major function | Movement of glucuronate and glucuronate conjugates across cell and organelle membranes, typically as an export step after glucuronidation [5,6]. |
| Representative transporters | MRP/ABCC family ABC exporters and other organic solute carriers [5,6,8]. |
| Physiological context | Drug and xenobiotic disposition, metabolite clearance, blood-brain barrier transport and red blood cell solute handling [1,3,8]. |
| Related enzymatic step | Glucuronidation by UDP-glucuronosyltransferases, which creates the glucuronate conjugate that is subsequently transported. |
What Is GO:0015738?
In plain terms, GO:0015738 describes the crossing of a membrane by glucuronate. The QuickGO definition states that it is the process in which glucuronate is transported across a lipid bilayer, from one side of a membrane to the other. This is a biological_process term, and its synonym is glucuronate transport. The definition deliberately focuses on the transport event itself rather than on the enzymes that synthesize glucuronate conjugates, so it covers both ATP-driven export by ABC transporters and other carrier-mediated translocation mechanisms that move glucuronate or glucuronate conjugates across membranes [5,6,8].
Why Is glucuronate transmembrane transport Important in Cell Biology?
GO:0015738 is important because glucuronidation is one of the most common routes of drug and xenobiotic metabolism, and the transport of the resulting glucuronate conjugates determines whether those metabolites are eliminated or retained [2,5]. ABC transporters such as MRP2 and related ABCC proteins are established export pumps for glucuronate conjugates, and their activity influences drug bioavailability, biliary excretion and toxicity [5,6]. Transport of glucuronate conjugates also occurs at the blood-brain barrier and in red blood cells, showing that this process is relevant beyond the liver and gut [3,8]. Consequently, annotating and studying GO:0015738 helps researchers interpret pharmacokinetic data, predict drug-drug interactions and understand diseases linked to impaired conjugate transport [1,6].
• Glucuronate transport is the exit step that follows glucuronidation, a major phase II drug-metabolizing reaction.
• MRP/ABCC transporters act as ATP-dependent export pumps for glucuronate, glutathione and sulfate conjugates, linking GO:0015738 to multidrug resistance and drug disposition [5,6].
• Transport of glucuronate conjugates across the blood-brain barrier affects the brain exposure of dietary and drug-derived metabolites.
• Red blood cells possess organic solute transport activity that can handle glucuronate-containing compounds, expanding the physiological scope of the term.
• Bacterial ABC importers of acidic polysaccharides provide structural models for glucuronate-containing substrate recognition.
• Altered glucuronate conjugate transport can contribute to cholestatic liver injury and drug-induced toxicity [5,6].
• The term supports pharmacokinetic modeling of drugs that undergo glucuronidation, such as steviol glucuronide and flavonoids [1,3].
• Studying GO:0015738 helps identify transporter-mediated drug-drug interactions involving glucuronidated metabolites [1,6].
• It provides a functional annotation framework for interpreting metabolomic and transporter knockout data [5,6].
• It connects carbohydrate acid metabolism to membrane biology and cellular detoxification [2,5].
What Happens During glucuronate transmembrane transport?
Formation of the glucuronate conjugate
In simple terms: First, a sugar-acid group called glucuronate is attached to a drug or other molecule inside the cell.
Glucuronate transmembrane transport usually begins after glucuronidation, in which UDP-glucuronosyltransferases transfer glucuronic acid from UDP-glucuronic acid to a substrate, forming a glucuronate conjugate. This conjugation reaction increases the water solubility of drugs, xenobiotics and endogenous compounds and is a prerequisite for their recognition by export transporters [2,5]. The resulting glucuronate conjugate is the substrate that is subsequently moved across a membrane during GO:0015738.
Recognition by membrane transporters
In simple terms: Next, specialized transporter proteins in the membrane recognize the glucuronate conjugate and prepare to move it across.
ATP-binding cassette transporters of the MRP/ABCC family are the best-characterized proteins that recognize glucuronate conjugates. They function as export pumps for conjugates with glutathione, glucuronate or sulfate, and their substrate specificity has been mapped in detail [5,6]. Structural and biochemical studies of bacterial ABC transporters involved in the import of acidic polysaccharides such as alginate provide insight into how glucuronate-containing substrates bind to transporter subunits. In mammalian cells, additional organic solute transporters can also participate in glucuronate conjugate handling in specific tissues.
Translocation across the lipid bilayer
In simple terms: The transporter then flips the glucuronate conjugate from one side of the membrane to the other.
During translocation, the transporter undergoes conformational changes that move the glucuronate conjugate across the lipid bilayer, from the cytoplasmic side to the extracellular or luminal side for export pumps [5,7]. For ABC exporters such as MRP proteins, this step is powered by ATP binding and hydrolysis, which drives the transport cycle [5,6]. The direction of transport depends on the transporter and cell type, but the defining feature of GO:0015738 is the crossing of the membrane by glucuronate.
Release and downstream fate of glucuronate
In simple terms: Finally, the glucuronate conjugate is released on the other side of the membrane and can be excreted or further processed.
After translocation, the glucuronate conjugate is released into the extracellular space, bile or another compartment, where it can be excreted or interact with other transporters [5,6]. Transport across the blood-brain barrier and in red blood cells shows that glucuronate conjugates can also distribute to and from specialized compartments [3,8]. The efficiency of this release step influences the overall clearance of glucuronidated compounds and is therefore relevant to drug pharmacokinetics [1,6].
Integration with cellular metabolism
In simple terms: This transport step is part of a larger metabolic network that detoxifies and clears compounds.
Glucuronate transmembrane transport is integrated with phase II metabolism, because the same conjugates that are exported can also be hydrolyzed or further modified in different tissues [2,5]. Studies of steviol glucuronide and flavonoid metabolites show that transport of glucuronate conjugates can be modulated by co-administered drugs and natural compounds, indicating that GO:0015738 is a point of drug-drug interaction [1,3]. This integration makes the term useful for systems-level analyses of detoxification and metabolite distribution [5,6].
Key Genes Involved in GO:0015738 glucuronate transmembrane transport
The genes and proteins most directly associated with glucuronate transmembrane transport are membrane transporters that recognize and translocate glucuronate conjugates, together with the enzymes that create those conjugates.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCC2 (MRP2) | ATP-dependent export pump for glucuronate, glutathione and sulfate conjugates [5,6] | Biliary excretion of glucuronidated drugs; cholestasis and drug-induced liver injury models [5,6] |
| ABCC1 (MRP1) | Multidrug resistance-associated protein that exports conjugated metabolites [5,6] | Transport of glucuronate conjugates in cancer cells and drug resistance studies [5,6] |
| ABCC3 (MRP3) | Basolateral export of glucuronate conjugates from polarized cells [5,6] | Hepatocyte and intestinal models of conjugate efflux [5,6] |
| ABCC4 (MRP4) | Transport of conjugated organic anions, including glucuronate conjugates [5,6] | Kidney and blood-brain barrier transport studies [3,6] |
| UGT1A1 | Glucuronosyltransferase that forms glucuronate conjugates such as bilirubin glucuronide | Source of glucuronate conjugates for transport assays; jaundice and drug metabolism models |
| UGT2B7 | Glucuronosyltransferase that conjugates drugs and endogenous compounds | Generates glucuronate substrates for transporter studies |
| SLCO1B1 | Organic anion transporting polypeptide that can influence conjugate handling | Uptake and disposition studies of glucuronidated compounds |
| SLCO1B3 | Liver-specific organic anion transporter involved in conjugate uptake | Hepatocyte models of glucuronate conjugate flux |
| ABCG2 (BCRP) | ABC transporter that can export conjugated metabolites | Intestinal and blood-brain barrier transport models [3,6] |
| SLC22A family | Organic cation/anion transporters that handle small organic solutes | Red blood cell and renal transport studies |
| OATP family | Organic anion transporting polypeptides that mediate uptake of conjugates | Drug-drug interaction studies involving glucuronidated metabolites [1,6] |
| Alginate ABC transporter subunits | Bacterial ABC transporter that imports acidic polysaccharides containing glucuronate | Structural and mechanistic studies of glucuronate-containing substrate recognition |
| MRP-related bacterial transporters | Prokaryotic models of conjugate transport | Comparative transport biology and structural biology |
| UGT1A6 | Glucuronosyltransferase that conjugates small phenols | In vitro generation of glucuronate conjugates for transport assays |
| UGT1A9 | Glucuronosyltransferase with broad substrate range | Metabolite generation for transporter screening |
| ABCC5 | ABC transporter with overlapping conjugate specificity [5,6] | Functional redundancy studies in knockout models [5,6] |
| ABCC6 | ABC transporter linked to ectopic mineralization and conjugate transport [5,6] | Disease models of impaired conjugate export [5,6] |
| SLC17A family | Vesicular transporters that can handle organic anions | Organelle-level transport studies |
How Is glucuronate transmembrane transport Regulated?
Glucuronate transmembrane transport is regulated at multiple levels. The expression and activity of MRP/ABCC exporters can be modulated by transcriptional and post-transcriptional mechanisms, and their substrate handling is influenced by the availability of glucuronate conjugates produced by UGT enzymes [2,5]. Co-administered drugs and natural compounds can inhibit or compete with glucuronate conjugate transport, as shown for steviol glucuronide and selected drugs and natural compounds. In addition, the transport of flavonoid metabolites across the blood-brain barrier indicates that tissue-specific barriers regulate glucuronate conjugate distribution. Because ABC transporters use ATP, cellular energy status and the overall metabolic state can also influence transport capacity [5,6]. These layers of regulation make GO:0015738 a dynamic process rather than a fixed membrane property [1,5,6].
glucuronate transmembrane transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCC2 (MRP2) | Cholestasis and drug-induced liver injury due to impaired biliary excretion of glucuronate conjugates [5,6] | Hepatocyte knockout and knock-in models with transport assays [5,6] |
| ABCC1 (MRP1) | Multidrug resistance in cancer through export of conjugated drugs [5,6] | Cancer cell line knockout and overexpression models [5,6] |
| ABCC6 | Ectopic mineralization and connective tissue disorder linked to conjugate transport [5,6] | Knockout mouse and patient-derived cell models [5,6] |
| UGT1A1 | Hyperbilirubinemia and altered glucuronidation capacity | Isogenic cell lines with point mutations in UGT1A1 |
| ABCB1/ABCG2 | Blood-brain barrier transport and drug resistance [3,6] | In vitro blood-brain barrier models with transporter knockout [3,6] |
Drug-induced liver injury and cholestasis
Impaired export of glucuronate conjugates from hepatocytes can lead to intracellular accumulation of metabolites and cholestatic liver injury. MRP2 and related ABCC transporters are key export pumps for glucuronate conjugates, and their dysfunction or inhibition is associated with altered biliary excretion and hepatotoxicity [5,6]. Because many drugs are glucuronidated, transport capacity for glucuronate conjugates is a determinant of drug-induced liver injury risk [2,5].
Multidrug resistance in cancer
ABC transporters that export glucuronate conjugates also contribute to multidrug resistance by removing conjugated and unconjugated drugs from cancer cells [5,6]. Overexpression of MRP/ABCC proteins can reduce intracellular drug concentrations and limit the efficacy of chemotherapy, making glucuronate conjugate transport relevant to cancer pharmacology [5,6]. Studies of caffeic acid and its activity in hepatocarcinoma illustrate how natural compounds and their conjugates can interact with these pathways.
Blood-brain barrier and central nervous system exposure
Glucuronate conjugates of dietary and drug-derived compounds can cross a human blood-brain barrier model, indicating that transport at the neurovascular interface influences brain exposure to these metabolites. This has implications for the central nervous system effects of flavonoids and other polyphenols, whose glucuronidated forms are often the predominant circulating species. Transporters such as ABCC4 and ABCG2 may contribute to this barrier function [3,6].
Metabolic and transporter-related disorders
Alterations in glucuronate conjugate transport can affect the clearance of endogenous compounds and contribute to metabolic disturbances. Red blood cell organic solute transport activity shows that glucuronate-containing compounds can be handled outside the liver, expanding the potential disease relevance of GO:0015738. In addition, ABCC6 dysfunction is linked to ectopic mineralization, highlighting that conjugate transport proteins have tissue-specific physiological roles [5,6].
From glucuronate transmembrane transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate transporter reduce glucuronate conjugate export? | CRISPR knockout of ABCC2 or ABCC1 in hepatocyte or cancer cell lines [5,6] |
| Does a specific transporter residue determine glucuronate conjugate recognition? | Point-mutation knock-in of the transporter substrate-binding site [5,7] |
| Can a fluorescent or tagged transporter be used to follow glucuronate transport in live cells? | Tagged knock-in of the transporter with a fluorescent protein [5,6] |
| Does overexpression of a transporter increase glucuronate conjugate efflux? | Transporter overexpression in a low-expressing cell line [5,6] |
| Which transporters handle glucuronate conjugates at the blood-brain barrier? | In vitro blood-brain barrier model with transporter knockout or knockdown |
| How does glucuronidation capacity affect downstream transport? | UGT knockout or overexpression combined with transport assays [2,5] |
How to Study the glucuronate transmembrane transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled conjugate transport assay | Directional flux of glucuronate conjugates across membranes [5,6] | Quantifying export activity of MRP/ABCC transporters [5,6] |
| Fluorescent conjugate imaging | Real-time transport and subcellular localization [3,5] | Live-cell studies of glucuronate conjugate handling [3,5] |
| LC-MS metabolomics | Levels of glucuronate conjugates in cells and media [1,2] | Detecting changes in conjugate production and export [1,2] |
| Membrane vesicle assay | ATP-dependent transport in a cell-free system [5,6] | Mechanistic studies of transporter specificity [5,6] |
| Blood-brain barrier model transport | Permeability of glucuronate conjugates across an endothelial barrier | Central nervous system exposure studies |
| Red blood cell transport assay | Organic solute transport activity in erythrocytes | Non-hepatic glucuronate conjugate handling |
| Structural biology of ABC transporters | Substrate-binding site and conformational states | Understanding glucuronate-containing substrate recognition |
| CRISPR knockout transport phenotyping | Effect of transporter loss on glucuronate flux [5,6] | Causal assignment of transport activity to a gene [5,6] |
Transport assays with radiolabeled or fluorescent glucuronate conjugates
Direct measurement of glucuronate transmembrane transport can be performed using radiolabeled or fluorescent glucuronate conjugates in polarized cell monolayers or membrane vesicles. Such assays quantify the export or uptake of glucuronate conjugates and can be combined with transporter inhibitors to assign the transport activity to specific proteins [1,5,6]. These methods are the primary way to test whether a candidate gene contributes to GO:0015738 [5,6].
Metabolomics and conjugate profiling
Liquid chromatography-mass spectrometry can profile glucuronate conjugates in cells and media, revealing whether transport is altered when a transporter is knocked out or overexpressed [1,2]. Metabolomic profiling of steviol glucuronide and flavonoid metabolites has been used to study transport and interactions with drugs and natural compounds [1,3]. This approach links GO:0015738 to global metabolic changes [1,3].
Membrane vesicle and reconstitution assays
Inside-out membrane vesicles prepared from transporter-expressing cells allow ATP-dependent transport of glucuronate conjugates to be measured in a cell-free system [5,6]. Reconstitution and structural studies of bacterial ABC transporters that import acidic polysaccharides provide mechanistic insight into substrate recognition and translocation. These assays help distinguish direct transport from indirect metabolic effects [5,7].
Imaging and barrier models
Fluorescent glucuronate conjugates and transporter-specific antibodies can be used to visualize transport in live cells and in blood-brain barrier models. Such imaging approaches reveal the subcellular route and directionality of glucuronate transport [3,5]. They are particularly useful for studying transport across tight epithelial and endothelial barriers.
How CRISPR Can Be Used to Study GO:0015738 glucuronate transmembrane transport
Knockout
CRISPR knockout of candidate transporters such as ABCC2 or ABCC1 provides a direct test of whether a gene is required for glucuronate transmembrane transport [5,6]. Knockout cells can be challenged with glucuronate conjugates and analyzed by transport assays or metabolomics to quantify loss of export [1,5]. This approach is essential for assigning function to specific MRP/ABCC family members [5,6].
Point Mutation
Point-mutation knock-in can be used to dissect the substrate-binding residues or catalytic residues of transporters involved in glucuronate conjugate recognition [5,7]. By introducing disease-associated or rationally designed mutations, researchers can test which residues are required for glucuronate transport without deleting the entire protein [5,7]. This is particularly informative for ABC transporters with broad substrate specificity [5,6].
Knock-in
Knock-in of fluorescent or affinity tags allows endogenous transporters to be tracked and purified while preserving native regulation [5,6]. Tagged knock-in models can be used to measure transporter localization, turnover and interaction with glucuronate conjugates in physiologically relevant cells [5,6]. This approach complements overexpression systems by avoiding artifacts of supraphysiological expression [5,6].
Overexpression
Overexpression of a candidate transporter in a low-expressing cell line can increase glucuronate conjugate efflux and establish sufficiency for transport [5,6]. Overexpression models are useful for testing substrate specificity and inhibitor sensitivity of glucuronate transport [1,5]. They can also be combined with metabolomics to determine how increased transport changes intracellular conjugate levels [1,5].
How EDITGENE Supports glucuronate transmembrane transport Research
Researchers studying glucuronate transmembrane transport-related genes often need to determine whether a candidate gene is causally involved in moving glucuronate conjugates across membranes, or whether it merely correlates with altered metabolite levels. Establishing causality requires precise genetic models in which the candidate transporter can be deleted, mutated, tagged or overexpressed in a controlled cellular background. EDITGENE provides these models together with functional readouts that connect genotype to transport phenotype.
Contact EDITGENE today to design your custom CRISPR model for glucuronate transmembrane transport research.
Frequently Asked Questions About glucuronate transmembrane transport
What is glucuronate transmembrane transport?
Glucuronate transmembrane transport (GO:0015738) is the process in which glucuronate is transported across a lipid bilayer, from one side of a membrane to the other.
What genes are involved in glucuronate transmembrane transport?
The best-characterized genes are ABC transporters of the MRP/ABCC family, such as ABCC1, ABCC2, ABCC3 and ABCC4, which export glucuronate conjugates [5,6]. UGT enzymes such as UGT1A1 produce the glucuronate conjugates that are subsequently transported.
Why is glucuronate transport important for drug metabolism?
Many drugs are glucuronidated, and their export by transporters determines clearance and exposure; inhibition or loss of transport can alter drug levels and toxicity [1,2,5].
Which transporters export glucuronate conjugates?
MRP/ABCC proteins function as ATP-dependent export pumps for conjugates with glutathione, glucuronate or sulfate [5,6].
Can glucuronate conjugates cross the blood-brain barrier?
Yes, flavonoid metabolites including glucuronate conjugates have been shown to cross a human blood-brain barrier model.
What is the difference between glucuronidation and glucuronate transport?
Glucuronidation is the enzymatic attachment of glucuronic acid to a substrate by UGT enzymes, while glucuronate transmembrane transport is the subsequent movement of the glucuronate conjugate across a membrane [2,5].
How can I study glucuronate transmembrane transport in the lab?
Common approaches include radiolabeled or fluorescent conjugate transport assays, membrane vesicle assays, LC-MS metabolomics and CRISPR knockout of candidate transporters [1,5,6].
Is glucuronate transport relevant to cancer?
Yes, ABC transporters that export glucuronate conjugates contribute to multidrug resistance by reducing intracellular drug concentrations [5,6].
Do red blood cells transport glucuronate conjugates?
Red blood cells possess organic solute transport activity that can handle glucuronate-containing compounds.
What experimental models are used for GO:0015738 research?
Knockout, point-mutation, knock-in and overexpression cell models, together with transport and metabolomic assays, are widely used to study glucuronate transmembrane transport [1,5,6].
Conclusion
GO:0015738 (glucuronate transmembrane transport) captures a critical interface between phase II metabolism and membrane transport. The process is driven largely by MRP/ABCC exporters that recognize glucuronate conjugates and move them across lipid bilayers, with additional contributions from organic solute transporters in specialized tissues [5,6,8]. Because glucuronidation is a major route of drug and xenobiotic clearance, the transport step has direct consequences for pharmacokinetics, drug-drug interactions and toxicity [1,2,6]. Studying this term requires precise genetic models and functional transport assays. CRISPR knockout, point-mutation, knock-in and overexpression approaches allow researchers to assign transport activity to specific genes and to test how glucuronate conjugate flux changes in disease-relevant contexts [1,5,6]. As metabolomic and imaging technologies advance, GO:0015738 will remain a key annotation for understanding how cells handle glucuronate-containing molecules [3,7].
References
- 1. Wang M et al.. 2015. Transmembrane transport of steviol glucuronide and its potential interaction with selected drugs and natural compounds.. Food Chem Toxicol 86:217-24 PMID: 26525112
- 2. Meech R et al.. 1997. Structure and function of uridine diphosphate glucuronosyltransferases.. Clin Exp Pharmacol Physiol 24(12):907-15 PMID: 9406655
- 3. Faria A et al.. 2014. Flavonoid metabolites transport across a human BBB model.. Food Chem 149:190-6 PMID: 24295694
- 4. Espíndola KMM et al.. 2019. Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma.. Front Oncol 9:541 PMID: 31293975
- 5. Homolya L et al.. 2003. Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate.. Biofactors 17(1-4):103-14 PMID: 12897433
- 6. Zhou SF et al.. 2008. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development.. Curr Med Chem 15(20):1981-2039 PMID: 18691054
- 7. Maruyama Y et al.. 2015. Structure of a Bacterial ABC Transporter Involved in the Import of an Acidic Polysaccharide Alginate.. Structure 23(9):1643-1654 PMID: 26235029
- 8. Culliford SJ et al.. 1995. Activation of a novel organic solute transporter in mammalian red blood cells.. J Physiol 489 ( Pt 3)(Pt 3):755-65 PMID: 8788940
